(Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker with Ki of 0.56-2.1 μM for NMDA receptor; IC 50 s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively. Lanicemine shows antidepressant effects [1].

Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects [1]. Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also affects these networks without the broader systems-level disruptions typical of ketamine [1]. Animal Model: Male Sprague-Dawley rats [1] Dosage: 3, 10 or 30 mg/kg Administration: Intraperitoneal Result: Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity.